These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2965972)

  • 21. Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells.
    Berends D; van der Kwast TH; de Both NJ; Mulder PG
    Cancer Immunol Immunother; 1989; 28(2):123-30. PubMed ID: 2783887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD4-CD8- T cell receptor alpha beta T cells: generation of an in vitro major histocompatibility complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection.
    Mieno M; Suto R; Obata Y; Udono H; Takahashi T; Shiku H; Nakayama E
    J Exp Med; 1991 Jul; 174(1):193-201. PubMed ID: 1905338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of Ia+ reticulum cell sarcoma (RCS) growth in syngeneic SJL/J mice. I. Inhibition of tumor growth by passive administration of L3T4 monoclonal antibody before or after tumor inoculation.
    Ohnishi K; Bonavida B
    J Immunol; 1987 Jun; 138(12):4524-9. PubMed ID: 2953807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity.
    Awwad M; North RJ
    J Exp Med; 1988 Dec; 168(6):2193-206. PubMed ID: 2974065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preadministration of a T-suppressor factor enhances tumor immunity in DBA/2 mice.
    Deal H; Steele JK; Stammers AT; Singhai R; Levy JG
    Cancer Immunol Immunother; 1989; 28(3):193-8. PubMed ID: 2493988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune surveillance: both CD3+ CD4+ and CD3+ CD8+ T cells control in vivo growth of P815 mastocytoma.
    Flamand V; Biernaux C; Van Mechelen M; Sornasse T; Urbain J; Leo O; Moser M
    Int J Cancer; 1990 Apr; 45(4):757-62. PubMed ID: 1691152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors.
    Dye ES; North RJ
    J Leukoc Biol; 1984 Jul; 36(1):27-37. PubMed ID: 6234371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-specific CD4(+) suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice.
    Fu T; Shen Y; Fujimoto S
    Int J Cancer; 2000 Sep; 87(5):680-7. PubMed ID: 10925362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.
    Nagarkatti M; Kaplan AM
    J Immunol; 1985 Aug; 135(2):1510-7. PubMed ID: 3159794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel method for in vitro depletion of T cells by monoclonal antibody-targeted photosensitization.
    Berki T; Németh P
    J Immunol Methods; 1998 Feb; 211(1-2):139-46. PubMed ID: 9617838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
    Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ
    J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Production of tumor-specific suppressor T cell hybridomas.
    Bear HD
    J Surg Res; 1987 Apr; 42(4):369-76. PubMed ID: 2437390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Experimental study of anti-tumor effect with conjugates of monoclonal antibodies and hematoporphyrin derivative].
    Xu SX; Wang NQ; Dong ZW
    Yao Xue Xue Bao; 1989; 24(6):401-6. PubMed ID: 2532854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin.
    Yokota S; Hara H; Luo Y; Seon BK
    Cancer Res; 1990 Jan; 50(1):32-7. PubMed ID: 2293557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.
    Melero I; Shuford WW; Newby SA; Aruffo A; Ledbetter JA; Hellström KE; Mittler RS; Chen L
    Nat Med; 1997 Jun; 3(6):682-5. PubMed ID: 9176498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Humoral mechanisms of the membrano-toxic effects of mastocytoma P815 and leukemia EL4 cells].
    Medvedev AE; Fuks BB
    Biull Eksp Biol Med; 1989 Aug; 108(8):194-6. PubMed ID: 2508789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection.
    Nakayama E; Uenaka A
    J Exp Med; 1985 Feb; 161(2):345-55. PubMed ID: 3871834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells.
    Rakhmilevich AL; North RJ; Dye ES
    Int J Cancer; 1993 Sep; 55(2):338-43. PubMed ID: 8103762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.